

# Olivier Chinot

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/12121173/olivier-chinot-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39  
papers

4,288  
citations

23  
h-index

42  
g-index

42  
ext. papers

5,408  
ext. citations

9.2  
avg, IF

4.53  
L-index

#	Paper	IF	Citations
39	Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.. <i>Oncologist</i> , <b>2022</b> , 27, 414-423	5.7	
38	Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.. <i>Acta Neuropathologica Communications</i> , <b>2022</b> , 10, 1	7.3	4
37	Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort. <i>Journal of Neuro-Oncology</i> , <b>2021</b> , 153, 55-64	4.8	2
36	Impact of depatuzizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 1-12	7.5	2
35	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 170-186	19.4	204
34	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdaa147	0.9	1
33	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , <b>2020</b> , 22, 684-693	1	62
32	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. <i>Neurology</i> , <b>2019</b> , 93, e1799-e1806	6.5	5
31	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1447-1457	1	19
30	Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients. <i>Anticancer Research</i> , <b>2019</b> , 39, 1035-1041	2.3	3
29	Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 142, 511-520	4.8	5
28	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , <b>2018</b> , 135, 601-615	14.3	54
27	Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study. <i>European Journal of Cancer</i> , <b>2017</b> , 73, 30-37	7.5	47
26	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , <b>2017</b> , 18, e315-e329	21.7	599
25	Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 132, 433-437	4.8	8
24	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1027-1037	59.2	525
23	Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. <i>Journal of Neurosurgery</i> , <b>2017</b> , 127, 660-669	3.2	27

22	Evidence-based management of adult patients with diffuse glioma - AuthorsUreply. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e430-e431	21.7	4
21	Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. <i>Cancer Biomarkers</i> , <b>2017</b> , 20, 435-441	3.8	10
20	Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 731-9 <sup>2.2</sup>	21.7	108
19	Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. <i>Oncotarget</i> , <b>2016</b> , 7, 61916-61929 <sup>3.3</sup>	3.3	34
18	Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1533-1542	21.7	77
17	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1521-1532 <sup>21.7</sup>	21.7	294
16	Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. <i>Neurosurgical Review</i> , <b>2014</b> , 37, 415-23; discussion 423-4	3.9	31
15	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e395-403	21.7	498
14	Predictive biomarkers investigated in glioblastoma. <i>Expert Review of Molecular Diagnostics</i> , <b>2014</b> , 14, 883-93	3.8	13
13	High-grade glioma in elderly patients: can the oncogeriatrician help?. <i>Clinical Interventions in Aging</i> , <b>2013</b> , 8, 1617-24	4	5
12	Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 110, 205-13	4.8	26
11	Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltransferase in a series of 100 glioblastoma patients. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 110, 1201-11	6.4	149
10	IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 105, 591-600	4.8	55
9	Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3050-5	2.2	167
8	Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. <i>Neuro-Oncology</i> , <b>2010</b> , 12, 725-35	1	130
7	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. <i>Neuro-Oncology</i> , <b>2010</b> , 12, 401-8	1	147
6	Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. <i>Human Pathology</i> , <b>2010</b> , 41, 815-23	3.7	16
5	Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. <i>Acta Neuropathologica</i> , <b>2010</b> , 120, 719-29	14.3	233

4	Up-front temozolomide in elderly patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , <b>2010</b> , 99, 89-94.	4.8	35
3	Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. <i>Cancer</i> , <b>2009</b> , 115, 4783-94	6.4	67
2	Radiotherapy for glioblastoma in the elderly. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1527-35	59.2	602
1	Deletions of chromosomes 1p and 19q are detectable on frozen smears of gliomas by FISH: usefulness for stereotactic biopsies. <i>Journal of Neuro-Oncology</i> , <b>2004</b> , 68, 141-9	4.8	18